|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-3-27
|
|
pubmed:abstractText |
Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in human cancers are associated with increased sensitivity to anilinoquinazoline EGFR inhibitors. To our knowledge no data have been reported on EGFR gene mutations in hormone refractory prostate cancer (HRPC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0270-4137
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2007 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
603-4
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17290443-Adenocarcinoma,
pubmed-meshheading:17290443-Adolescent,
pubmed-meshheading:17290443-Adult,
pubmed-meshheading:17290443-Antineoplastic Agents,
pubmed-meshheading:17290443-Drug Resistance, Neoplasm,
pubmed-meshheading:17290443-Drug Therapy, Combination,
pubmed-meshheading:17290443-Humans,
pubmed-meshheading:17290443-Male,
pubmed-meshheading:17290443-Mutation,
pubmed-meshheading:17290443-Neoplasms, Hormone-Dependent,
pubmed-meshheading:17290443-Prostate-Specific Antigen,
pubmed-meshheading:17290443-Prostatic Neoplasms,
pubmed-meshheading:17290443-Quinazolines,
pubmed-meshheading:17290443-Receptor, Epidermal Growth Factor
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
|
|
pubmed:affiliation |
Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology and University of Milan School of Medicine, Milano, Italy. Giuseppe.curigliano@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
